Parkinson'
Conditions
Interventions
Donepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks)
Placebo
Sponsors
Clinical Research Center, Utano National Hospital, National Hospital Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) UK brain bank Parkinson's disease diagnostic criteria (steps 1 and 2) 2) Hoehn-Yahr stages (I to III) 3) Not taking donepezil hydrochloride or other AchE inhibitors in the preceding 4 weeks. 4) Subjects who gave the written informed consent.
Exclusion criteria
Exclusion criteria: 1) Subjects taking anti-cholinergic drugs, including trihexyphenidyl, biperidien, profenamine, piroheptine, metixene, mazaticol, promethazine, cyproheptadine. 2) Subjects with diffuse Lewy body disease (according to third report of the DLB consortium) . 3) Present or previous diagnosis of schizophrenia. 4) Severe liver dysfunction or severe renal dysfuction. 5) Present or previous diagnosis of sick sinus syndrome 6) Present or previous diagnosis of broncheal asthma. 7) Subjects who investigators judge as inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in UPDRS-3 from the baseline condition | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in UPDRS-1, 2, and total UPDRS from the baseline condition | — |
Countries
Japan
Contacts
Public ContactHideyuki Sawada
Utano National Hospital, National Hospital Organization Clinical Research Center
Outcome results
None listed